PEPtalk

Two peptides, two halves of the same repair job. BPC-157 builds blood supply locally; TB-500 mobilizes repair cells systemically. Together they're the Wolverine stack — the most talked-about combination in the peptide world, and one with no human trials behind it.

In this episode:

• GLP pulse: a federal judge declines to block Lilly's Zepbound and Mounjaro ads in Novo Nordisk's false-advertising suit — what the ruling does and doesn't decide — plus fresh oral prescription numbers from the Fierce Pharma tracker.

• The deep dive: how BPC-157 and TB-500 each work, why the community pairs them, and what the animal evidence actually shows.

• The news: the HHS interim compounding policy meets the market — Superpower opens pre-orders for compounded BPC-157, TB-500, and MOTS-c, and the public comment window closes November 13.

• The catch: the policy covers one peptide per product, so a combined Wolverine vial falls outside it. Plus the sports ban, the evidence gap, and what's next (GHK-Cu, Monday November 9).

Everything we discuss is for research and informational purposes only. Not medical advice.

Sources:

• AminoWire, "Superpower opens compounded peptide pre-orders after HHS notice," October 31, 2026 — https://aminowire.news/news/2026/10/superpower-compounded-peptides-preorders/

• Thomson Reuters, "US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk," October 26, 2026 — https://krro.com/2026/10/26/us-judge-lets-eli-lilly-continue-ads-for-weight-loss-drugs-rules-against-novo-nordisk/

• Fierce Pharma, Oral GLP-1 Tracker (updated October 30, 2026) — https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill

• HHS interim enforcement-discretion policy on 503A compounding of six peptides, Federal Register Doc. 2026-22192, 91 FR 68526-68527 (published October 30, 2026); public comments due November 13, 2026, docket HHS-OASH-2026-0496

• National Community Pharmacists Association, "FDA grants enforcement discretion to compounding six peptides," October 29, 2026 — https://ncpa.org/newsroom/qam/2026/10/29/fda-grants-enforcement-discretion-compounding-six-peptides

• Healthline, "What's the Wolverine Peptide Stack and Is It Safe?" — https://www.healthline.com/health/wolverine-peptides

• BPC-157 systematic review (2025): 39 studies, 1993-2024, presented at the American Academy of Orthopaedic Surgeons

• TB-500 Achilles tendon study (2026): 32 rats, systemic treatment, load-to-failure significance; Philp et al. (2003) angiogenesis; Bock-Marquette et al., Nature (2004) cardiac repair

• FDA Pharmacy Compounding Advisory Committee, July 23-24, 2026: BPC-157 and TB-500 favorable recommendations (8-6-1), advisory only

A Spoke-Media production:

https://www.spoke-media.com

This week: the week's biggest story — HHS posts a draft enforcement-discretion policy for compounding six peptides (BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500) under section 503A, scheduled for Federal Register publication on October 30 — what it covers, what it doesn't, and where the critics stand.

Plus: Lilly's Retatrutide beats Ozempic more than two-to-one on weight loss in the Phase 3 TRANSCEND-T2D-2 head-to-head; the EY-Parthenon GLP-1 Consumer Impact Report finds 21% of US adults have now tried a GLP-1;

Lilly raises its full-year outlook on booming Mounjaro and Zepbound sales while its Foundayo pill lags estimates; and Ascletis files an IND for ASC39, an oral small-molecule amylin agonist.

For research and informational purposes only — not medical advice. Nothing on this show is a recommendation for any product or treatment.

Sources:

• Federal Register (public inspection, Doc. 2026-22192, Docket HHS-OASH-2026-0496) — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, posted October 28, 2026, scheduled for publication October 30, 2026: https://www.federalregister.gov/public-inspection/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances

• Reuters (Oct 28, 2026) — US health department to allow temporary sale of some unapproved peptides: https://www.reuters.com/legal/litigation/us-health-department-allow-temporary-sale-some-unapproved-peptides-2026-10-28/

• NCPA (Oct 29, 2026) — FDA grants enforcement discretion to compounding six peptides: https://ncpa.org/newsroom/qam/2026/10/29/fda-grants-enforcement-discretion-compounding-six-peptides

• AminoWire (updated Oct 28, 2026) — Peptide access policy goes to White House review; Appendix A names the six peptides: https://aminowire.news/news/2026/10/peptide-interim-access-policy-omb-review/

• Partnership for Safe Medicines (Oct 28, 2026) — Statement on the FDA and HHS enforcement discretion policy for 503A compounding: https://www.safemedicines.org/2026/10/statement-on-503a-peptide-enforcement.html

• Eli Lilly investor press release (Oct 28, 2026) — Lilly's Retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial: https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-greater-a1c-reduction-and-more

• ABC News / GMA Wellness (Oct 28, 2026) — New weight loss drug Retatrutide provides double the weight loss of Ozempic, Lilly says: https://abcnews.com/GMA/Wellness/new-weightloss-drug-retatrutide-double-weight-loss-ozempic/story?id=137614872

• EY-Parthenon GLP-1 Consumer Impact Report (released Oct 22, 2026): https://www.ey.com/en_us/newsroom/2026/10/glp-1-consumer-impact-report

• Food Business News (Oct 2026) — Snack consumption squeezed by surging GLP-1 adoption (21% of US adults have tried GLP-1s, up from 8% in 2024): https://www.foodbusinessnews.net/articles/31233-snack-consumption-squeezed-by-surging-glp-1-adoption

• Reuters (Oct 29, 2026) — Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges: https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-lifts-revenue-outlook-weight-loss-drug-sales-trims-profit-view-deal-2026-10-29/

• Stocktwits (Oct 28, 2026) — HIMS stock jumps 5% after HHS temporarily clears compounding of six peptides: https://stocktwits.com/news-articles/markets/equity/hims-stock-jumps-5-after-hhs-temporarily-clears-compounding-of-six-peptides/cZU9rvnR9Gn

• Ascletis Pharma / PR Newswire (Oct 25, 2026) — Ascletis announces FDA IND submission of ASC39, an oral small molecule selective amylin receptor agonist: https://www.morningstar.com/news/pr-newswire/20261025cn79691/ascletis-announces-fda-ind-submission-of-asc39-an-oral-small-molecule-selective-amylin-receptor-agonist-for-the-treatment-of-obesity

A Spoke-Media production:

https://www.spoke-media.com

This week: TB-500, the systemic half of the Wolverine stack — a synthetic fragment of thymosin beta-4, a 43-amino-acid protein found in almost every cell in the human body.

Jake and Cynthia unpack the mechanism (G-actin binding, cell migration, angiogenesis, the ILK-Akt survival pathway, anti-inflammatory signaling), the animal research on tendons, ligaments, heart and lung repair, the real evidence gap (encouraging reports, yet to be proven in human trials), the July 2026 FDA advisory vote, and why it's banned in sport. Plus a refreshed GLP pulse: the October 23 Pharmafile report on the indirect comparison of Lilly's oral Foundayo (orforglipron) against oral semaglutide; the latest oral GLP-1 prescription tracker; and Novo's new CagriSema analyses in women from the REDEFINE 1 trial.

For research and informational purposes only — not medical advice. Nothing on this show is a recommendation for any product or treatment.

Sources:

- Pharmafile (Oct 23, 2026) — Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison (ACHIEVE-3 vs PIONEER-PLUS, 52 weeks; 1.46 points greater weight reduction, 0.31 points greater HbA1c reduction; indirect comparison, not head-to-head): https://pharmafile.com/news/orforglipron-shows-weight-and-glucose-advantages-over-oral-semaglutide-in-indirect-comparison/

- Fierce Pharma (updated Oct 23, 2026) — The Oral GLP-1 Tracker: Novo's Wegovy pill vs Lilly's Foundayo (Wegovy pill ~173K prescriptions, Foundayo ~58K, down ~4% week over week; Novo ~75% of oral pill market, Lilly over 25%): https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill

- Reuters (Oct 20, 2026) — Novo's CagriSema helped women lose 25% of weight on average, analysis shows (REDEFINE 1: 25.0% mean weight loss at 68 weeks in 2,309 women vs 3.0% placebo; 26.7% / 24.8% / 23.1% across menopause stages; post hoc analyses, hypothesis-generating): https://dukecountry.fm/2026/10/20/novos-cagrisema-helped-women-lose-25-of-weight-on-average-analysis-shows/

- HealingMaps — TB-500 (thymosin beta-4 fragment) explainer: mechanism, WADA status, PCAC review: https://healingmaps.com/tb-500-thymosin-beta-4-fragment-wound-healing-peptide/

- PrimeLab Peptides — TB-500 tendon and ligament repair evidence (2026 rat Achilles study; 2013 rat MCL model): https://primelabpeptides.com/blogs/news/what-evidence-shows-tb-500-effectiveness-in-tendon-and-ligament-repair-post-injury

- PrimeLab Peptides — TB-500 and fibrosis/scar tissue (cardiac, lung fibrosis models): https://primelabpeptides.com/blogs/news/what-evidence-supports-tb-500-use-in-pulmonary-fibrosis-research

- Paragon Sports Medicine — TB-500 regulatory position, WADA S2 prohibition, 503A status: https://www.paragonsportsmedicine.com/peptides/tb-500

- TarzanOptimized — What is TB-500 (thymosin beta-4 fragment, systemic vs local repair): https://tarzanoptimized.com/blog/what-is-tb-500

- Frier Levitt — July 23–24, 2026 PCAC votes: six of seven peptides recommended for 503A Bulks List (TB-500 8–6): https://www.frierlevitt.com/news/fda-pcac-peptides-503a-compounding/

- Flow Wellness — July 2026 PCAC update: what the vote means and does not mean: https://flowwellness.com/new-peptides-may-be-available-soon/

- Impact Health Clinics — BPC-157/TB-500 FDA status: the July 2026 review, votes by substance: https://www.impacthealthclinics.com/blog/bpc-157-fda-status-2026

- Business Wire — Enhanced: PCAC vote context, Wolverine Stack (BPC-157 + TB-500) protocol: https://www.businesswire.com/news/home/20260727193803/en/Enhanced-Applauds-FDA-Advisory-Committees-Landmark-Vote-to-Expand-Legal-Compounding-Pathway-for-Peptides

Filed to the library as 010, and with that filing Sunday's Monday-production run now stands down for this slot — the weekly series itself is untouched.

A Spoke-Media production:

https://www.spoke-media.com

TOP STORY: Health Secretary Robert F. Kennedy Jr. says the Trump administration aims to create a regulated marketplace for peptides — "Americans are going to be buying these anyway. Our objective was to make sure that there is a regulated marketplace, so that what they're getting is what they claim to be, that is safe, that the factories are inspected." The sequel to the FDA's compounding-access policy story.

ACCESS VS. SAFETY: Apothecary Pharma's nationwide recall grows to 23 vials of compounded Tirzepatide plus one vial of NAD+ injection (Class II, no reported illnesses); Carolina Infusion's Class II recall of compounded Semaglutide, Tirzepatide, and Sermorelin syringes; an FDA warning letter to Empower Pharmacy; twenty state attorneys general warn about Chinese GLP-1 ingredients entering through the FDA's "Green List"; South Africa moves to tighten its compounding rules.

CONSUMER ECONOMICS: the GLP-1 supplement boom — a $74 billion market with no FDA preapproval requirement; plus one-liners on New Zealand premium food exports and GLP-1 costs vs. retirement savings.

PIPELINE: Ascletis posts positive preclinical data for a once-weekly oral amylin peptide pipeline; WuXi AppTec on why oral peptides can require 10–100x the drug ingredient.

BENEFITS RESEARCH: GLP-1 users with sleep apnea showed ~40% lower risk of acute respiratory failure (presented at CHEST 2026, not yet peer-reviewed).

For research and informational purposes only — not medical advice.

Sources:

- Reuters — "Kennedy says Trump administration aims for regulated market for peptides" (Oct 20, 2026): https://www.reuters.com/world/kennedy-says-trump-administration-aims-regulated-market-peptides-2026-10-20/

- Fox Business — Apothecary Pharma recall update, 23 vials incl. NAD+ injection (Oct 21, 2026)

- USA Today — "GLP-1 injections nationwide recall" (Oct 19, 2026): https://www.usatoday.com/story/money/consumer-protection/recalls-alerts/2026/10/19/glp-1-injections-nationwide-recall/92332991007/

- MedShadow — FDA Enforcement Report: Carolina Infusion compounded GLP-1 recalls (Oct 16, 2026): https://medshadow.org/drug-updates-recalls/fda-recalls-and-warnings/compounded-glp1-recalls-metoclopramide-tretinoin/

- FDA warning letter to Empower Pharmacy (dated Sept 18, 2026; public Sept 22, 2026)

- Regulatory Oversight / AL AG release — 20-state AGs letter on FDA "Green List" and Chinese GLP-1 ingredients (Oct 21, 2026)

- Reuters — "South Africa revises rules around customisation of weight-loss drugs" (Oct 14, 2026): https://www.reuters.com/legal/litigation/south-africa-revises-rules-around-customisation-weight-loss-drugs-2026-10-14/

- Reuters — "Weight-loss drug users turn to dietary supplements; doctors, regulators raise flags" (Oct 20, 2026): https://www.reuters.com/legal/litigation/weight-loss-drug-users-turn-dietary-supplements-doctors-regulators-raise-flags-2026-10-20/

- RNZ — "Rise of GLP-1 unlocking new opportunities for New Zealand's premium food exports" (Oct 19, 2026): https://www.rnz.co.nz/news/country/2036071/rise-of-glp-1-unlocking-new-opportunities-for-new-zealand-s-premium-food-exports

- Benefit News / Nationwide Retirement Institute survey — GLP-1 costs vs. retirement savings (Oct 21, 2026)

- PR Newswire via Morningstar — "Ascletis announces positive preclinical data for the most comprehensive once-weekly oral peptide pipeline" (Oct 19, 2026): https://www.morningstar.com/news/pr-newswire/20261019cn75171/ascletis-announces-positive-preclinical-data-for-the-most-comprehensive-once-weekly-oral-peptide-pipeline-for-the-treatment-of-obesity

- GlobeNewswire — "Peptide manufacturing trends: how oral dosing raises API demand" (WuXi AppTec, Oct 21, 2026): https://www.globenewswire.com/news-release/2026/10/21/3385365/0/en/peptide-manufacturing-trends-how-oral-dosing-raises-api-demand.html

- Medical Daily — "GLP-1, sleep apnea, acute respiratory failure" (CHEST 2026 presentation, Oct 19, 2026): https://www.medicaldaily.com/glp-1-sleep-apnea-acute-respiratory-failure-chest-2026-480137

A Spoke-Media production:

https://www.spoke-media.com

Peptide Overview:

A comprehensive walkthrough of "Peptides: small wonder?", the expert view published by SCOR (one of the world's largest reinsurance companies).

Jake and Cynthia cover what peptides actually are, who's using them and why — from GLP-1s to BPC-157 — the four ways people obtain them, the six categories of risk, how they compare to other drugs, and what it all means in plain language. Ends with a simplified overview tying it together.

For research and informational purposes only — not medical advice.

**Sources:**

- SCOR — "Peptides: small wonder?" Expert View (September 2026): https://www.scor.com/en/expert-views/peptides-small-wonder

A Spoke-Media production:

https://www.spoke-media.com

This week: BPC-157, the most talked-about healing peptide on the internet — a 15-amino-acid fragment from human gastric juice with thirty years of animal research and encouraging reports, but yet to be proven in human trials.

Jake and Cynthia unpack the mechanism (angiogenesis, fibroblast activity, gut-barrier repair), the striking tendon/ligament/gut data in animals, the real evidence gap, and the July 2026 FDA advisory vote everyone is misreading.

Plus the GLP pulse: the FDA's interim peptide-compounding policy names BPC-157, Europe's regulator backs Lilly's oral GLP-1 Foundayo, and Biomea posts Phase 1 data for its oral small-molecule BMF-650.

For research and informational purposes only — not medical advice. Nothing on this show is a recommendation for any product or treatment.

**Sources:**

- Reuters — FDA/HHS submit interim peptide-compounding policy for White House review (Oct 15): https://www.reuters.com/legal/litigation/us

-fda-takes-step-change-peptide-compounding-policy-2026-10-15/

- AP via Stocktwits — BPC-157 named in compounding policy reporting; Hims stock +6% (Oct 15): https://stocktwits.com/news-articles/markets/equity/hims-stock-peptide-hopes-trump-administration-reviews-plan-unlock-market/cZx0VkeRBr8

- EMA — CHMP recommends EU approval for Foundayo/orforglipron (Oct 16): https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2026

- Reuters — Lilly's Foundayo wins European backing (Oct 16): https://www.reuters.com/legal/litigation/eli-lillys-weight-loss-pill-wins-backing-europe-2026-10-16/

- GlobeNewswire — Biomea Phase 1 results for oral small-molecule GLP-1 BMF-650 (Oct 13): https://www.globenewswire.com/news-release/2026/10/13/3380154/0/en/biomea-fusion-announces-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist.html

- Brainflow — BPC-157 complete guide (2025 AAOS systematic review, 39 studies): https://brainflow.co/complete-guide-to-BPC-157-benefits-dosage/

- Marketing or Science — BPC-157 evidence vs hype, July 2026 PCAC vote: https://marketingorscience.com/articles/pharma/2026/07/BPC-157-healing-peptide

- Lambert Medical Practice — BPC-157 peptide guide (mechanisms, gut/tendon data): https://lambertmedicalpractice.co.uk/blog/BPC-157-peptide-guide/

- Top Doctor Magazine — PCAC vote 8–6, ulcerative colitis indication: https://topdoctormagazine.com/news/regenerative-medicine-peptide-evidence-hype/

- OneDayMD — clinician peptide guide (PCAC six-of-seven, regulatory status): https://www.onedaymd.com/2026/02/peptides-guide.html

- Frier Levitt — PCAC 503A legal analysis (advisory vs binding): https://www.frierlevitt.com/news/fda-pcac-peptides-503a-compounding/

- Blog by Donna — PCAC vote explainer ("recommendation is not a rule"): https://blogbydonna.com/the-fda-peptide-vote-didnt-legalize-BPC-157/

A Spoke-Media production:

https://www.spoke-media.com

This week the biggest story isn't a trial readout — it's the economy reshaping itself around GLP-1s.

Jake and Cynthia unpack Gallup's new numbers (15% of US adults have tried a GLP-1 for weight loss, up from 3% two years ago), the Cornell grocery-receipts study (household spending down 5.3%, savory snacks down 10%), and the BCG survey (active users spending 11% more on high-protein foods). Plus the industry response: Olive Garden's Lighter Portions menu, Nestlé's GLP-1 nutrition line, and Walmart covering Ozempic and Mounjaro at zero cost for employees with type 2 diabetes in 2027.

Also: a Blood Cancer Journal study of 140,000 matched patients finds no blood-cancer risk signal from GLP-1s.

Semaglutide extends lifespan 12% in mice (Nature); Pharma's GLP-1 brain-drug pipeline heats up with Lilly's Brenipatide for alcohol use disorder; and the amylin wave builds with Petrelintide (10.7%), Survodutide (13.1%), and Trevogrumab's 70% muscle-loss prevention.

For research and informational purposes only — not medical advice.

**Sources:**

- Gallup — GLP-1 usage reaches new high (15% ever-used, 11% current; May–June 2026 survey): https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx

- Medical Xpress — Cornell/Journal of Marketing Research grocery spending study (Dec 2025): https://medicalxpress.com/news/2025-12-ozempic-foods-americans-buy.html

- Green Queen — BCG GLP-1 food consumption survey (+11% protein, +15% fruit/veg): https://www.greenqueen.com.hk/boston-consulting-group-glp-1-food-consumption-spending-protein-fiber-survey/

- Yahoo Lifestyle — Olive Garden "Lighter Portions" menu, GLP-1 users cited (Oct 13, 2026): https://www.yahoo.com/lifestyle/articles/restaurant-menus-getting-smaller-glp-160004125.html

- Mexico Business News — Novo Nordisk CEO on food industry rethink (Oct 12, 2026): https://mexicobusiness.news/health/news/glp-1-drugs-push-food-industry-rethink-portions-products

- WebProNews — GLP-1 drugs shrink appetites; food company earnings calls (Oct 12, 2026): https://www.webpronews.com/glp-1-drugs-shrink-appetites-and-grocery-bills-pharma-giants-reap-billions-while-snack-makers-scramble/

- Food Navigator — Nestlé developing GLP-1 nutrition products (Oct 8, 2026): https://www.foodnavigator.com/Article/2026/10/08/how-glp-1-weight-loss-drugs-are-reshaping-food-and-beverage-innovation/

- CNBC — Walmart $0 GLP-1s for T2D employees in 2027 (Oct 13, 2026): https://www.cnbc.com/2026/10/13/walmart-glp-1s-inhalers-employee-benefits.html

- Nature / Blood Cancer Journal — GLP-1RAs and hematologic malignancy risk, TriNetX matched cohort (Oct 12, 2026): https://www.nature.com/articles/s41408-026-01618-4

- CNN — Semaglutide extends lifespan in older mice, Nature study (Oct 13, 2026): https://www.cnn.com/2026/10/13/health/glp-1-drugs-anti-aging

- UC Berkeley — GLP-1 treatment extends lifespan in older healthy mice (Sept 2026): https://vcresearch.berkeley.edu/news/glp-1-treatment-extends-lifespan-older-healthy-mice.

- Nature — Pharma's GLP-1 brain-drug pipeline: brenipatide, KP405, Baseline Therapeutics (Oct 13, 2026): https://www.nature.com/articles/d41586-026-03252-3

- Pharmacy Times — Petrelintide Phase 2 ZUPREME-1: up to 10.7% at 42 weeks (Oct 6, 2026): https://www.pharmacytimes.com/view/petrelintide-yields-up-to-10-7-weight-loss-with-mild-gi-effects

- GlobeNewswire — Zealand Pharma: Survodutide SYNCHRONIZE-2 up to 13.1% at 76 weeks (Oct 1, 2026): https://www.globenewswire.com/news-release/2026/10/01/3372565/0/en/zealand-pharma-announces-boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-.html

- GlobeNewswire — Regeneron: Trevogrumab COURAGE prevents 70% of GLP-1 muscle loss (Oct 1, 2026): https://www.globenewswire.com/news-release/2026/10/01/3373155/0/en/phase-2-courage-trial-confirms-trevogrumab-prevents-lean-mass-and-muscle-loss-during-glp-1-receptor-agonist-induced-weight-loss.html

A Spoke-Media production:

https://www.spoke-media.com

Last week: Sermorelin, the elegant idea. This week: Tesamorelin - its bigger sibling, and the evidence heavyweight of the growth hormone peptide world.

Jake and Cynthia unpack Tesamorelin — the full forty-four amino acid growth hormone releasing factor with a protective chemical cap, two Phase three trials, visceral fat down fourteen to eighteen percent, lean body mass up, liver fat down, and an FDA approval (Egrifta) with a formulation modernization: Egrifta WR, approved March 2025 and in pharmacies since September 2025.

Plus the honest limits: a narrow approved use, maintenance required, and long-term cardiovascular safety still an open file.

Also: the weekly GLP pulse — the growing evidence that GLP-1s curb drug and alcohol cravings (PBS NewsHour), plus new research on compulsive gambling and shopping (CBS News).

For research and informational purposes only — not medical advice.

Sources:

• PBS NewsHour — The evidence suggesting GLP-1s can curb drug and alcohol cravings (Oct 7, 2026): https://www.pbs.org/newshour/show/the-evidence-suggesting-glp-1s-can-curb-drug-and-alcohol-cravings

• CBS News — Doctor explains how GLP-1 drugs could help reduce gambling, shopping addiction (Oct 9, 2026): https://www.cbsnews.com/news/glp-1-drugs-wharton-study-impulsive-spending/

• Medscape — Tesamorelin reduces visceral fat in HIV-associated lipodystrophy (Phase 3 data): https://www.medscape.com/viewarticle/732450

• Theratechnologies / http://Drugs.com — FDA Approval for EGRIFTA WR (tesamorelin F8), March 25, 2025: https://www.drugs.com/newdrugs/theratechnologies-receives-fda-approval-egrifta-wr-tesamorelin-f8-excess-visceral-abdominal-fat-6482.html

• Theratechnologies — Availability of EGRIFTA WR, September 5, 2025: https://www.cbj.ca/theratechnologies-announces-availability-of-egrifta-wr-tesamorelin-for-injection-to-reduce-excess-abdominal-fat-in-adults-with-hiv-and-lipodystrophy/

• Stanley & Grinspoon — Effect of Tesamorelin on Liver Fat and Visceral Fat in HIV-Infected Patients With Abdominal Fat Accumulation (JAMA / PMC): https://pmc.ncbi.nlm.nih.gov/articles/PMC4363137/

• Peptpedia — Tesamorelin (Egrifta): FDA-Approved, Visceral Fat Data: https://peptpedia.org/peptide/tesamorelin

A Spoke-Media production:

https://www.spoke-media.com

This week: both Lilly and Novo converged on $499/month cash pricing — and we walk the whole price ladder from list price to TrumpRx to the gray market.

Plus: Petrelintide's Phase 2 amylin data (up to 10.7% at 42 weeks with placebo-like tolerability) and its diabetes sister trial, retatrutide's low-dose readout (12.7% at just 4 mg), Trevogrumab's muscle-preservation data (70% of MRI-measured muscle loss prevented), Survodutide's Phase 3 diabetes trial (up to 13.1%),

CagriSema's data blitz ahead of an expected October FDA decision, the WHO's first childhood-obesity guidelines vs. strong teen GLP-1 data, Orforglipron's heart-safety clearance, a compounded-glutathione recall, and two-year data on J&J's oral peptide for psoriasis.

For research and informational purposes only — not medical advice. Nothing on this show is a recommendation for any product or treatment.

**Sources:**

- The Educated Patient — Lilly + Novo reduce GLP-1 costs in the post-shortage era ($499 cash pricing): https://www.theeducatedpatient.com/view/eli-lilly-novo-nordisk-reduce-glp-1-costs-in-post-shortage-era

- Pharmaphorum — Novo Nordisk cuts GLP-1 prices for cash buyers (NovoCare): https://pharmaphorum.com/news/novo-nordisk-cuts-glp-1-prices-cash-buyers

- Retail TouchPoints — TrumpRx.gov lower-price promise (MFN pricing, GoodRx integration): https://www.retailtouchpoints.com/features/news-briefs/trumprx-gov-promises-lower-prices-on-popular-prescription-drugs

- White House fact sheet — GLP-1 Bridge Medicare program ($50 copay, 600,000 seniors): https://www.whitehouse.gov/fact-sheets/2026/09/fact-sheet-president-donald-j-trump-announces-lower-drug-prices-for-all-50-state-medicaid-programs/

- Biocare Nutrition — GLP-1 cost without insurance: https://biocarenutrition.com/blogs/biocare-blog/glp-1-cost-without-insurance.

- Dispense Times — the GLP-1 showdown: TrumpRx, compounding crackdowns, and the new era of drug pricing: https://dispensetimes.com/the-glp-1-showdown-trumprx-compounding-crackdowns-and-the-new-era-of-drug-pricing/

- Zealand Pharma announcement — petrelintide ZUPREME-1 Phase 2 data, The Lancet Diabetes & Endocrinology publication, EASD 2026 presentation: https://business.theeveningleader.com/theeveningleader/article/gnwcq-2026-9-29-zealand-pharma-to-present-additional-data-from-phase-2-zupreme-1-trial-for-petrelintide-at-easd-2026-and-announces-publication-of-trial-results-in-the-lancet-diabetes-and-endocrinology

- Reuters (Oct 7, 2026) — petrelintide ZUPREME-2 in type 2 diabetes (up to 9.2% at 28 weeks): https://www.reuters.com/business/healthcare-pharmaceuticals/zealand-roches-obesity-drug-helps-patients-lose-up-92-weight-mid-stage-trial-2026-10-07/

- Eli Lilly press release (Jul 23, 2026) — retatrutide Phase 3 (29.8 lb / 12.7% at 4 mg; FDA filing Q1 2027): https://lilly.mediaroom.com/2026-07-23-Lillys-triple-agonist,-retatrutide,-successful-in-two-additional-Phase-3-obesity-trials,-delivering-significant-improvements-in-weight-and-A1C?asPDF=1

- Regeneron press release (Oct 1, 2026) — COURAGE Phase 2 trevogrumab muscle-loss prevention (70% MRI substudy): https://www.globenewswire.com/news-release/2026/10/01/3373155/0/en/phase-2-courage-trial-confirms-trevogrumab-prevents-lean-mass-and-muscle-loss-during-glp-1-receptor-agonist-induced-weight-loss.html

- Zealand Pharma press release (Oct 1, 2026) — survodutide SYNCHRONIZE-2 Phase 3 (up to 13.1% at 76 weeks, NEJM): https://www.globenewswire.com/news-release/2026/10/01/3372565/0/en/zealand-pharma-announces-boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-.html

- TradingView weekly recap — HRS-1596 licensing and CagriSema 52-week EASD results: https://www.tradingview.com/news/tradingview:67ef0d4ddfa76:0-weekly-recap-hrs-1596-licensing-deal-and-cagrisema-52-week-trial-results/

- WHO — launch of guidelines on integrated management of obesity in children and adolescents (Oct 7, 2026): https://www.who.int/news-room/events/detail/2026/10/07/default-calendar/launch-of-who-guidelines--integrated-management-of-obesity-in-children-and-adolescents

- Reuters (Oct 7, 2026) — WHO endorses lifestyle changes over GLP-1 drugs in child-obesity fight: https://www.reuters.com/business/healthcare-pharmaceuticals/who-endorses-lifestyle-changes-over-glp-1-drugs-child-obesity-fight-2026-10-07/

- Seoul Economic Daily (Oct 6, 2026) — ecnoglutide Phase 1b in obese adolescents (up to 12.1% at 20 weeks): https://en.sedaily.com/technology/2026/10/06/hk-innons-glp-1-obesity-drug-cuts-teen-weight-up-to-121

- Pharmacy Times (Oct 1, 2026) — orforglipron ACHIEVE-4 CV safety vs. insulin glargine: https://www.pharmacytimes.com/view/orforglipron-shows-cv-safety-vs-insulin-glargine-in-achieve-4

- USA Today (Oct 2, 2026) — Greenwich Rx compounded-glutathione recall: https://www.usatoday.com/story/money/consumer-protection/recalls-alerts/2026/10/02/injectables-drugs-recalled-greenwich-rx/92055116007/

- Johnson & Johnson press release (Oct 2, 2026) — ICOTYDE (icotrokinra) 2-year ICONIC-TOTAL data, EADV 2026: https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-new-icotyde-icotrokinra-data-in-difficult-to-treat-plaque-psoriasis-with-proven-durability-through-2-years-affirming-its-use-as-a-powerful-first-line-systemic-therapy

A Spoke-Media production:

https://www.spoke-media.com

Sermorelin is having a moment.

Jake and Cynthia unpack the growth hormone peptide everyone's pivoting to: what it is (a copy of your body's own GHRH signal), how it works (pulsatile, feedback-intact), what the research actually shows (nocturnal GH up, lean mass up in men, skin thickness up in both sexes), and why it's trending now that ipamorelin is restricted. Plus its surprising pedigree: an FDA-approved drug (Geref, 1997) that left the market for business reasons, not safety. Honest bottom line included.

Also: the weekly GLP pulse — Retatrutide goes mainstream, CagriSema food-noise data, and a $2.6B oral GLP-1 deal.

For research and informational purposes only — not medical advice.

Sources:

• Prime Lab Peptides — sermorelin pituitary signaling (Khorram 1997): https://primelabpeptides.com/blogs/news/how-does-sermorelin-influence-pituitary-signaling-pathways-in-endocrine-research

• Sermorelin myths vs. reality (Geref 1997/2008, 503A compounding): https://medium.com/@esochabiakasikhi/sermorelin-peptide-myths-vs-reality-bdeea758b588

• Scientific American — growth hormone peptides and the evidence: https://www.scientificamerican.com/article/growth-hormone-peptides-promise-to-stall-aging-but-does-the-science-stack-up/

• The BMJ — retatrutide TRIUMPH Phase 3: http://www.bmj.com/content/395/bmj-2026-101016

• Pharmacy Times — CagriSema curbs food noise: https://www.pharmacytimes.com/view/cagrisema-curbs-food-noise-organ-fat-in-patients-with-obesity-t2d-respectively

• Business News Today — Novo–Hengrui $2.6B deal: https://business-news-today.com/hengrui-lands-2-6bn-novo-nordisk-deal-for-experimental-weekly-oral-obesity-drug/

A Spoke-Media production:

https://www.spoke-media.com

EASD 2026 in Milan turned into a Lilly showcase — and Jake and Cynthia round up the whole week.

Stories this week:

(1) Retatrutide's full Phase 3 TRIUMPH-1 data — up to 25% weight loss at 80 weeks, plus knee osteoarthritis and sleep apnea improvements — and TRIUMPH-2 in type 2 diabetes published in The Lancet; Lilly expects to file with the FDA by end of March 2027.

(2) Lilly's amylin + tirzepatide combo EloraTZP: 23.3% at 48 weeks heading to Phase 3, with a real tolerability question — plus the wider amylin stacking moment.

(3) Boehringer/Zealand's survodutide Phase 3 SYNCHRONIZE-2: 13.1% at 76 weeks, published in NEJM the same day.

(4) Novo's oral strategy: up to $2.6B for ex-China rights to Hengrui's weekly oral GLP-1/GIP, real-world data on switching to the Wegovy pill, and Wegovy liver-fat normalization.

(5) The FDA's warning letter to Empower Pharmacy over mass-produced compounded GLP-1s — its fourth. Plus a market check: LLY dipped on great news, NVO down ~24% YTD.

For research and informational purposes only — not medical advice.

**Sources:**
- Cardiac Wire — TRIUMPH-1 full Phase 3: https://cardiacwire.com/a-new-king-of-the-glp-1s-could-be-crowned/
- USA Today — TRIUMPH-2 / Lilly FDA filing plans: https://www.usatoday.com/story/money/personal-finance/healthcare/2026/09/30/retatrutide-glp-1-eli-lilly-weight-loss/92019663007/
- BioSpace — EloraTZP Phase 2b: https://www.biospace.com/drug-development/superior-weight-loss-blood-sugar-control-propel-lillys-amylin-gip-glp-1-combo-into-phase-3
- Zealand Pharma — SYNCHRONIZE-2: https://mfn.se/one/a/zealand-pharma/zealand-pharma-announces-boehringer-ingelheims-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-with-obesity-and-type-2-diabetes-a9e0d011
- Business News Today — Novo–Hengrui $2.6B deal: https://business-news-today.com/hengrui-lands-2-6bn-novo-nordisk-deal-for-experimental-weekly-oral-obesity-drug/
- Reuters — OCTANE real-world switching study: https://www.reuters.com/legal/litigation/patients-switching-to-novo-nordisks-wegovy-pill-shots-lose-more-weight-real-2026-09-30/
- Becker's Hospital Review — FDA warning letter to Empower Pharmacy: https://www.beckershospitalreview.com/pharmacy/fda-flags-sterility-concerns-at-major-glp-1-compounder/

A Spoke-Media production:

https://www.spoke-media.com

Welcome to Peptalk! In our pilot episode, Jake and Cynthia go deep on NAD+ (nicotinamide adenine dinucleotide) — one of the most talked-about molecules in the peptide world right now, even though it's not technically a peptide at all.

We open with a fast GLP-1 pulse: retatrutide's showstopping EASD 2026 data (28.3% weight loss at 80 weeks), a warning about gray-market vials, Lilly's oral orforglipron vs. oral semaglutide, and Novo's deal with Nanexa on long-acting delivery.

Then the deep dive: what NAD+ actually does in the body (mitochondrial energy, sirtuin activation, DNA repair), the formats it's sold in (IV drips, injections, oral NR/NMN precursors, nasal spray), and what a 2026 systematic review really found — precursors reliably raise blood NAD+ metabolites, but functional outcomes are mixed, and there are zero clinical trials of IV NAD+ for wellness. Plus the cell-membrane problem, the GLP-1 stacking rationale, safety data, and an honest bottom line.

For research and informational purposes only — not medical advice.

**Sources:**
- StackTrax NAD+ guide: https://stacktrax.com/guides/nad-plus
- Frontiers in Aging — IV NAD+ and precursors in wellness: https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2026.1887175/full
- NPR/WAMC — "Marketers say NAD+ pills and infusions can boost longevity. What's the evidence?": https://www.wamc.org/2026-05-11/marketers-say-nad-pills-and-infusions-can-boost-longevity-whats-the-evidence
- Key Wellness — NAD+ therapy research summary: https://www.keytwellness.com/post/nad-therapy-cellular-energy-and-what-the-research-shows
- Abby Langer — "The NAD+ Anti-Aging Hype, Explained": https://bitemebyabbylanger.substack.com/p/can-nad-really-slow-aging
- Medical Daily — EASD 2026 retatrutide data preview: https://www.medicaldaily.com/easd-2026-retatrutide-mounjaro-wegovy-pill-data-preview-479203
- Morningstar/PR Newswire — Lilly's orforglipron vs. oral semaglutide: https://www.morningstar.com/news/pr-newswire/20260929de57460/lillys-foundayo-orforglipron-172-mg-showed-greater-weight-loss-and-a1c-reduction-than-oral-semaglutide-25-mg-among-adults-with-type-2-diabetes-in-a-new-indirect-treatment-comparison

A Spoke-Media production:

https://www.spoke-media.com